Acrivon Therapeutics Inc [NASDAQ: ACRV] gained 17.09% or 0.34 points to close at $2.33 with a heavy trading volume of 12998740 shares.
It opened the trading session at $2.255, the shares rose to $2.46 and dropped to $2.13, the range by which the price of stock traded the whole day. The daily chart for ACRV points out that the company has recorded 64.08% gains over the past six months.
If we look at the average trading volume of 1.32M shares, ACRV reached to a volume of 12998740 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Acrivon Therapeutics Inc [ACRV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACRV shares is $11.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACRV stock is a recommendation set at 1.22. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for Acrivon Therapeutics Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 05, 2025. While these analysts kept the previous recommendation, KeyBanc Capital Markets raised their target price to Overweight. The new note on the price target was released on January 31, 2025, representing the official price target for Acrivon Therapeutics Inc stock. Previously, the target price had yet another raise to $16, while Ladenburg Thalmann analysts kept a Buy rating on ACRV stock.
The Price to Book ratio for the last quarter was 0.51, with the Price to Cash per share for the same quarter was set at 4.37.
Trading performance analysis for ACRV stock
Acrivon Therapeutics Inc [ACRV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.48. With this latest performance, ACRV shares gained by 21.99% in over the last four-week period, additionally plugging by 64.08% over the last 6 months – not to mention a drop of -61.30% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACRV stock in for the last two-week period is set at 70.17, with the RSI for the last a single of trading hit 0.1700, and the three-weeks RSI is set at 0.1500 for Acrivon Therapeutics Inc [ACRV]. The present Moving Average for the last 50 days of trading for this stock 1.7200, while it was recorded at 2.0300 for the last single week of trading, and 2.4300 for the last 200 days.
Acrivon Therapeutics Inc (ACRV) Capital Structure & Debt Analysis
According to recent financial data for Acrivon Therapeutics Inc. ( ACRV), the Return on Equity (ROE) stands at -47.87%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -44.18%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Acrivon Therapeutics Inc’s Return on Invested Capital (ROIC) is -59.22%, showcasing its effectiveness in deploying capital for earnings.
Acrivon Therapeutics Inc (ACRV) Efficiency & Liquidity Metrics
Based on Acrivon Therapeutics Inc’s (ACRV) latest financial statements, the Debt-to-Equity Ratio is 0.02%, indicating its reliance on debt financing relative to shareholder equity.
Acrivon Therapeutics Inc (ACRV) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Acrivon Therapeutics Inc. (ACRV) effectively leverages its workforce, generating an average of -$1102051.28 per employee. The company’s liquidity position is robust, with a Current Ratio of 10.31% and a Quick Ratio of 10.31%, indicating strong ability to cover short-term liabilities.
Acrivon Therapeutics Inc [ACRV]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Acrivon Therapeutics Inc posted -0.59/share EPS, while the average EPS was predicted by analysts to be reported at -0.59/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ACRV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Acrivon Therapeutics Inc go to 3.18%.
An analysis of Institutional ownership at Acrivon Therapeutics Inc [ACRV]
There are presently around $56.68%, or 71.42%% of ACRV stock, in the hands of institutional investors. The top three institutional holders of ACRV stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 8.34 million shares, which is approximately 23.083%. PERCEPTIVE ADVISORS LLC, holding 5.36 million shares of the stock with an approximate value of $$31.09 million in ACRV stocks shares; and PERCEPTIVE ADVISORS LLC, currently with $$12.31 million in ACRV stock with ownership which is approximately 5.8745%.
